Microfluidic Controllable Preparation of Iodine‐131‐Labeled Microspheres for Radioembolization Therapy of Liver Tumors

Advanced Healthcare Materials, Journal Year: 2023, Volume and Issue: 12(21)

Published: June 2, 2023

Transcatheter arterial radioembolization (TARE) is of great significance for the treatment advanced hepatocellular carcinoma (HCC). However, existing radioembolic microspheres still have problems such as non-degradability, non-uniform size, and inability to directly monitor in vivo, which hinders development TARE. In this paper, a novel agent, 131 I-labeled methacrylated gelatin (131 I-GMs), prepared HCC. Water-in-oil (W/O) emulsion templates are by simple one-step microfluidic method obtain (GMs) after UV irradiation. A series GMs with uniform controllable size obtained adjusting flow rate each fluid. Both air-dried freeze-dried can quickly restore their original shape good monodispersity, elasticity, biocompatibility. The radiolabeling experiments show that I efficiently bind chloramine-T method, I-GMs radioactive stability vitro. results vivo TARE rats be well retained hepatic artery inhibitory effect on progression liver cancer, showing potential

Language: Английский

---

Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(17), P. 2321 - 2331

Published: April 29, 2024

The advent of cutting-edge systemic therapies has driven advances in the treatment hepatocellular carcinoma (HCC), and therapeutic strategies with multiple modes delivery have been shown to be more efficacious than monotherapy. However, mechanisms underlying this innovative modality not elucidated.

Language: Английский

---

Treatment strategies for solitary hepatocellular carcinoma: comparative outcomes of radiofrequency ablation vs. laparoscopic liver resection based on tumor location

Surgical Endoscopy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 4, 2025

Language: Английский

---

Integrating Navigation-Assisted Ablation in the Locoregional Treatment of Hepatocellular Carcinoma

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(2), P. e240694 - e240694

Published: Feb. 29, 2024

Importance With the increasing prevalence of hepatocellular carcinoma (HCC), ablative therapy is a critical treatment option to achieve cancer-free state. The anatomic location tumor can be challenge, and select hepatic locations require laparoscopic-assisted strategies safely reach treat lesion. Objective To assess association real-time ultrasonography-augmented navigation for HCC ablation with patient survival, operative time, rate incomplete ablations. Design, Setting, Participants This retrospective case-control study was conducted among prospectively collected database more than 750 patients who were treated without use at single quaternary medical center from June 2011 January 2021. Data analyzed October 2022 through 2023. Exposure Real-time navigation. Main Outcomes Measures primary outcome ablations in undergoing vs Secondary outcomes included overall survival (OS), progression-free (PFS), time. Results analytic cohort 467 (mean [SD] age, 62.4 [7.8] years; 355 male [76.0%]; 21 Hispanic [4.5%], 67 non-Hispanic Black [14.5%], 347 Non-Hispanic White [75.0%] 463 race ethnicity data). most common etiology liver disease hepatitis C infection (187 data [40.0%]), 348 458 TMN staging (76.0%) had TNM stage 1 disease. There 187 individuals 280 Patients underwent navigation-assisted likely have 2 based on (62 183 [33.9%] 47 275 [17.1%] data; P < .002) higher mean (SD) number lesions (1.3 [0.5] 1.2 lesions; = longer operation time (113.2 [29.4] 109.6 [32.3] minutes; .04). also tumors segment 8 (59 [32.1%] 53 [19.3%] .005) less 4 (20 [10.9%] 54 [19.6%]; .005). Overall recurrence after 10.0 (12.5) months, similar rates no differences (10 [9.2%] 10 [10.5%]; .32), OS, or PFS between Conclusions Relevance In this study, associated comparable navigation, although locally advanced These findings suggest that cancer should considered as useful tool treating challenging tumors.

Language: Английский

---

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality

Liver Cancer, Journal Year: 2023, Volume and Issue: 12(6), P. 565 - 575

Published: Jan. 1, 2023

Introduction: Because of recent developments in treatments for hepatocellular carcinoma (HCC), methods determining suitable therapy initial or recurrent HCC have become important. This study used artificial intelligence (AI) findings to establish a system predicting prognosis patients at time reoccurrence based on clinical data as reference selection treatment modalities. Methods: As training cohort, 5,701 observations obtained the and each subsequent recurrence from 1,985 single center 2000 2021 were used. The validation cohort included 5,692 multiple centers treatment. An AI calculating (PRAID) was constructed 25 factors noted then predictive prognostic values 1- 3-year survival both cohorts evaluated. Results: After exclusion lacking regarding albumin-bilirubin (ALBI) grade tumor-node-metastasis stage Liver Cancer Study Group Japan, 6th edition (TNM-LCSGJ 6th), ALBI-TNM-LCSGJ (ALBI-T) modified ALBI-T scores confirmed that similar. area under curve prediction 0.841 (sensitivity 0.933 [95% CI: 0.925–0.940], specificity 0.517 0.484–0.549]) 0.796 0.806 0.790–0.821], 0.646 0.624–0.668]), respectively. Conclusion: present PRAID might provide useful information related short medium decision-making best therapeutic modality cases.

Language: Английский

---

Liver Cancer: Improving Standard Diagnosis and Therapy

Cancers, Journal Year: 2023, Volume and Issue: 15(18), P. 4602 - 4602

Published: Sept. 17, 2023

In 2020, liver cancer ranked sixth for incidence (841,000 cases) and fourth deaths globally (782,000 [...]

Language: Английский

---

Albumin–Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4167 - 4167

Published: Dec. 13, 2024

Background/Objectives: Radiofrequency ablation (RFA) is an important local treatment for hepatocellular carcinoma (HCC). This study aimed to evaluate the characteristics of tumor recurrence after RFA and analyze predictors survival in patients with HCC. Methods: We retrospectively reviewed data from treatment-naïve HCC who underwent between 2008 2017 at four tertiary hospitals South Korea. Results: A total 636 treated were enrolled study. The mean age was 66.3 ± 10.4 years, 75.0% being male. Most (96.7%) had underlying liver cirrhosis, viral hepatitis (types B C) accounted most cases. average maximum size 2.2 0.9 cm, 84.3% tumors single lesions. During follow-up period, 331 experienced recurrence, 95.5% cases intrahepatic one-fifth occurring site. or transarterial chemoembolization as subsequent therapy recurrence. Multivariate analysis revealed that age, albumin–bilirubin (ALBI) grade, Child–Pugh class status independent factors associated Only ALBI grade significantly mortality. Additionally, differentiated recurrence-free overall Kaplan–Meier curve. Conclusions: independently prognosis following RFA. grading system can help clinicians identify high-risk patients, optimize strategies, enhance patient care.

Language: Английский

---